MX348637B - Anticuerpos y composiciones anti-her3. - Google Patents

Anticuerpos y composiciones anti-her3.

Info

Publication number
MX348637B
MX348637B MX2013004897A MX2013004897A MX348637B MX 348637 B MX348637 B MX 348637B MX 2013004897 A MX2013004897 A MX 2013004897A MX 2013004897 A MX2013004897 A MX 2013004897A MX 348637 B MX348637 B MX 348637B
Authority
MX
Mexico
Prior art keywords
compositions
antibodies
her3 antibodies
her3
recombinant
Prior art date
Application number
MX2013004897A
Other languages
English (en)
Spanish (es)
Other versions
MX2013004897A (es
Inventor
Koefoed Klaus
Wandahl Pedersen Mikkel
Jacobsen Helle
Original Assignee
Symphogen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen As filed Critical Symphogen As
Publication of MX2013004897A publication Critical patent/MX2013004897A/es
Publication of MX348637B publication Critical patent/MX348637B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2013004897A 2010-11-01 2011-10-31 Anticuerpos y composiciones anti-her3. MX348637B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40878210P 2010-11-01 2010-11-01
DKPA201000988 2010-11-01
DKPA201100672 2011-09-05
US201161531407P 2011-09-06 2011-09-06
PCT/IB2011/054835 WO2012059858A1 (en) 2010-11-01 2011-10-31 Anti-her3 antibodies and compositions

Publications (2)

Publication Number Publication Date
MX2013004897A MX2013004897A (es) 2013-07-15
MX348637B true MX348637B (es) 2017-06-22

Family

ID=59014867

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013004899A MX347981B (es) 2010-11-01 2011-10-31 Composicion de anticuerpos pan-her.
MX2013004897A MX348637B (es) 2010-11-01 2011-10-31 Anticuerpos y composiciones anti-her3.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2013004899A MX347981B (es) 2010-11-01 2011-10-31 Composicion de anticuerpos pan-her.

Country Status (13)

Country Link
US (1) US9217039B2 (enExample)
EP (3) EP2635605B1 (enExample)
JP (2) JP6186277B2 (enExample)
KR (2) KR101862832B1 (enExample)
AU (2) AU2011324871B2 (enExample)
CA (2) CA2816519C (enExample)
DK (1) DK2635604T3 (enExample)
ES (2) ES2692379T3 (enExample)
IL (2) IL225953A0 (enExample)
MX (2) MX347981B (enExample)
PL (1) PL2635604T3 (enExample)
TW (1) TW201231066A (enExample)
WO (2) WO2012059858A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2540146C2 (ru) * 2008-08-29 2015-02-10 Симфоген А/С Композиции рекомбинантных антител против рецептора эпидермального фактора роста
US8883149B2 (en) 2008-09-15 2014-11-11 Yeda Research And Development Co. Ltd. Antibody combinations and use of same for treating cancer
MX2012007340A (es) 2009-12-22 2012-08-01 Roche Glycart Ag Anticuerpos anti/her3 y usos de los mismos.
KR101862832B1 (ko) 2010-11-01 2018-05-30 심포젠 에이/에스 Ｐａｎ―ｈｅｒ 항체 조성물
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
CA2828043A1 (en) * 2011-03-15 2012-09-20 Merrimack Pharmaceuticals, Inc. Overcoming resistance to erbb pathway inhibitors
WO2012156975A1 (en) * 2011-05-16 2012-11-22 Yeda Research And Development Co. Ltd. COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER
KR20230114317A (ko) * 2011-07-01 2023-08-01 암젠 인크 포유동물 세포 배양
EP3608340A1 (en) 2011-11-23 2020-02-12 Medlmmune, LLC Binding molecules specific for her3 and uses thereof
EP2831115A1 (en) * 2012-03-27 2015-02-04 F. Hoffmann-La Roche AG Diagnosis and treatments relating to her3 inhibitors
HK1202431A1 (en) 2012-05-02 2015-10-02 Symphogen A/S Humanized pan-her antibody compositions
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
PL3508502T3 (pl) 2013-09-20 2023-07-17 Bristol-Myers Squibb Company Kombinacja przeciwciał anty-lag-3 i przeciwciał anty-pd-1 w leczeniu raka
WO2015048008A2 (en) 2013-09-24 2015-04-02 Medimmune, Llc Binding molecules specific for her3 and uses thereof
WO2015157634A1 (en) 2014-04-11 2015-10-15 Kolltan Pharmaceuticals, Inc. Anti-erbb antibodies and methods of use thereof
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US10526416B2 (en) 2014-09-08 2020-01-07 Yeda Research And Development Co. Ltd. Anti-HER3 antibodies and uses of same
WO2016038610A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
IL250902B (en) 2014-09-16 2022-08-01 Symphogen As Anti-met antibodies and compositions
EP3176183A1 (en) 2015-12-02 2017-06-07 Yeda Research and Development Co. Ltd Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki)
JP2018536682A (ja) 2015-12-11 2018-12-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｅｇｆｒ及び／またはｅｒｂｂ３遮断に耐性のある腫瘍の成長を低減または防止するための方法
CA3010056A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
MA49042A (fr) 2017-04-05 2020-02-12 Symphogen As Polythérapies ciblant pd-1, tim-3 et lag-3
CN118356488A (zh) 2017-05-30 2024-07-19 百时美施贵宝公司 包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物
PT3631454T (pt) 2017-05-30 2023-11-23 Bristol Myers Squibb Co Tratamento de tumores positivos para lag-3
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
MX2021002690A (es) * 2018-09-07 2021-05-12 Pfizer Anticuerpos anti-avb8 y composiciones y usos de los mismos.
CN114426578B (zh) * 2019-02-14 2025-03-21 美勒斯公司 结合egfr、her2及her3的结合部分的组合
SG11202108737RA (en) * 2019-02-14 2021-09-29 Merus Nv Combinations of binding moieties that bind egfr, her2 and her3.
JP7774293B2 (ja) * 2019-07-24 2025-11-21 国立研究開発法人科学技術振興機構 抗体酵素の革新的製造技術
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
WO2022144836A1 (en) 2020-12-31 2022-07-07 Sanofi Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123
TW202413419A (zh) 2022-05-27 2024-04-01 法商賽諾菲公司 與ｎｋｐ４６和ｂｃｍａ變體結合之具有ｆｃ工程化的自然殺手（ｎｋ）細胞接合物
TW202500584A (zh) 2023-05-19 2025-01-01 法商施維雅藥廠 抗met抗體、抗體-藥物結合物、組合物及其用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968511A (en) * 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
EP1728802A3 (en) * 1996-03-27 2006-12-13 Genentech, Inc. ErbB3 antibodies
AUPQ105799A0 (en) * 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
SI2857516T1 (sl) 2000-04-11 2017-09-29 Genentech, Inc. Multivalentna protitelesa in njihove uporabe
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
NZ541458A (en) 2003-01-07 2006-04-28 Symphogen As Method for manufacturing recombinant polyclonal proteins
EP1609803A4 (en) * 2003-03-31 2006-05-24 Chugai Pharmaceutical Co Ltd MODIFIED ANTIBODY AGAINST CD22 AND ITS USE
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
CA2574146C (en) 2004-07-20 2015-06-30 Symphogen A/S A procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line
KR20190126461A (ko) 2004-07-22 2019-11-11 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
CN101115849A (zh) 2004-12-07 2008-01-30 健泰科生物技术公司 选择her抑制剂疗法的患者
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
WO2008031531A1 (en) * 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
BRPI0808055A2 (pt) * 2007-02-16 2013-07-30 Merrimack Pharmaceuticals Inc anticorpo monoclonal isolado ou porÇço do mesmo que se liga ao antÍgeno, composiÇço, Ácido nucleico isolado, vetor de expressço, cÉlula hospedeira, hibridoma, kit, uso de um anticorpo monoclonal isolado ou porÇço do mesmo que se liga ao antÍgeno, mÉtodo para diagnosticar um cÂncer associado com erbb3 em um paciente, e, anticorpo
KR101805140B1 (ko) * 2007-03-01 2017-12-05 심포젠 에이/에스 재조합 항-표피 성장 인자 수용체 항체 조성물
MX2009012526A (es) 2007-05-25 2009-12-09 Symphogen As Metodo para fabricar una proteina policlonal recombinante.
CA2702322A1 (en) 2007-11-22 2009-05-28 Symphogen A/S A method for characterization of a recombinant polyclonal protein
RU2010147652A (ru) 2008-04-23 2012-05-27 Симфоген А/С (Dk) Способы производства поликлонального белка
AU2009281721A1 (en) 2008-08-15 2010-02-18 Merrimack Pharmaceuticals, Inc. Methods and systems for predicting response of cells to a therapeutic agent
RU2540146C2 (ru) * 2008-08-29 2015-02-10 Симфоген А/С Композиции рекомбинантных антител против рецептора эпидермального фактора роста
US20110224094A1 (en) 2008-10-06 2011-09-15 Symphogen A/S Method for identifying and selecting drug candidates for combinatorial drug products
NZ594665A (en) * 2009-03-20 2013-08-30 Genentech Inc Bispecific anti-her antibodies
BRPI1012589A2 (pt) 2009-04-07 2016-03-22 Roche Glycart Ag anticorpos bi-específicos anti-erbb-3/anti-c-met
ES2537100T3 (es) * 2009-04-07 2015-06-02 Roche Glycart Ag Anticuerpos biespecíficos trivalentes
CA2759792A1 (en) 2009-04-29 2010-11-04 Trellis Bioscience, Inc. Improved antibodies immunoreactive with heregulin-coupled her3
SG177560A1 (en) * 2009-07-06 2012-03-29 Hoffmann La Roche Bi-specific digoxigenin binding antibodies
SG178509A1 (en) * 2009-08-21 2012-04-27 Merrimack Pharmaceuticals Inc Antibodies against the ectodomain of erbb3 and uses thereof
EP2486052A4 (en) 2009-10-09 2013-05-01 Merck Sharp & Dohme GENERATION, LABELING AND USE OF ANTI-HER3 ANTIBODIES
LT2719708T (lt) 2009-11-13 2018-02-12 Daiichi Sankyo Europe Gmbh Medžiaga ir būdai, skirti su her-3 susijusių ligų gydymui arba prevencijai
TW201141519A (en) * 2010-03-04 2011-12-01 Symphogen As Anti-HER2 antibodies and compositions
CN105968206B (zh) 2010-04-09 2020-01-17 Aveo制药公司 抗erbb3抗体
MY162825A (en) * 2010-08-20 2017-07-31 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
KR101862832B1 (ko) 2010-11-01 2018-05-30 심포젠 에이/에스 Ｐａｎ―ｈｅｒ 항체 조성물

Also Published As

Publication number Publication date
TW201231066A (en) 2012-08-01
MX2013004897A (es) 2013-07-15
JP2014503189A (ja) 2014-02-13
WO2012059857A3 (en) 2012-07-19
AU2011324871B2 (en) 2016-05-19
CA2816519C (en) 2019-01-15
EP2635605A1 (en) 2013-09-11
CA2816520C (en) 2017-11-21
AU2011324870B2 (en) 2015-01-29
IL225954B (en) 2018-05-31
KR101862832B1 (ko) 2018-05-30
AU2011324870A1 (en) 2013-01-31
EP2635604A2 (en) 2013-09-11
EP3156421B1 (en) 2018-06-06
IL225954A0 (en) 2013-07-31
WO2012059858A1 (en) 2012-05-10
KR20140026336A (ko) 2014-03-05
ES2616961T3 (es) 2017-06-14
EP2635605A4 (en) 2014-10-22
CA2816520A1 (en) 2012-05-10
AU2011324871A1 (en) 2013-05-09
MX2013004899A (es) 2013-07-15
US20130287684A1 (en) 2013-10-31
EP2635604B1 (en) 2016-11-30
JP6033783B2 (ja) 2016-11-30
IL225953A0 (en) 2013-07-31
KR101773120B1 (ko) 2017-08-30
DK2635604T3 (en) 2017-02-27
CA2816519A1 (en) 2012-05-10
WO2012059857A2 (en) 2012-05-10
EP3156421A1 (en) 2017-04-19
JP2014503188A (ja) 2014-02-13
EP2635605B1 (en) 2018-07-25
ES2692379T3 (es) 2018-12-03
US9217039B2 (en) 2015-12-22
KR20140026337A (ko) 2014-03-05
MX347981B (es) 2017-05-22
JP6186277B2 (ja) 2017-08-23
PL2635604T3 (pl) 2017-09-29

Similar Documents

Publication Publication Date Title
MX2013004897A (es) Anticuerpos y composiciones anti-her3.
IN2014KN00848A (enExample)
PH12014502419A1 (en) Specific binding proteins and uses thereof
MX354481B (es) Anticuerpos dkk1 y métodos de uso.
TN2015000396A1 (en) Antibody drug conjugates
MX2020010639A (es) Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer.
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
EA201200999A1 (ru) Способы лечения рака молочной железы
PH12013500353A1 (en) Novel antigen binding proteins
PH12014500483A1 (en) Anti-erbb3 antibodies and uses thereof
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
MX357965B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar.
PH12012501157A1 (en) Anti-her3 antibodies and uses thereof
MY184628A (en) Afucosylated anti-fgfr2iiib antibodies
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
MX2014012978A (es) Regiones de anticuerpo modificado y sus usos.
EA201291065A1 (ru) Антитела против vla-4
PH12015500752A1 (en) Her3 antigen binding proteins binding to the beta-hairpin of her3
PH12015500751A1 (en) Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and beta-hairpin of her4
TN2012000466A1 (en) Humanized anti cxcr4 antibodies for the treatment of cancer
TN2015000277A1 (en) Bmp-6 antibodies
MX2016014416A (es) Anticuerpos anti-her3 que se unen a la horquilla beta de her3.
PH12013500432A1 (en) Anti-vegfr-3 antibody compositions
MX2013003859A (es) Polimorfos de picropodofilina b o c para su uso en la terapia del cancer.
HK1196856A (en) C10rf32 antibodies, and uses thereof for treatment of cancer

Legal Events

Date Code Title Description
FG Grant or registration